Asthma. Asthma, unspecified
Conditions
Interventions
Intervention 1: Starting the trial:
As mentioned above all symptomatic asthmatic subjects whom were resistant to treatment with inhaled corticosteroids, Salmetrol, Montelukast and theophilline will b
and paraclinical tests such as spirometry (Superspiro, Micromedical instruments, England) and FENO (No Breath, Bedfont Medical instruments, England). Subjects whom showed complete improving or side ef
Treatment - Drugs
Starting the trial:
As mentioned above all symptomatic asthmatic subjects whom were resistant to treatment with inhaled corticosteroids, Salmetrol, Montelukast and theophilline will be entered in th
and paraclinical tests such as spirometry (Superspiro, Micromedical instruments, England) and FENO (No Breath, Bedfont Medic
Second phase:
Subjects will be evaluated for primary outcomes. Evaluations consist of clinical evaluation as like as symptoms (cough and dyspnea) and sign (wheeze) and clinical improvement of asthma
Third (last) phase: In the last month (fifth month) both groups will receive both extracts and trial will be finished with evaluation of outcome parameters for last time. Outcome parameters will be ev
and paraclinical tests such as spirometry (Superspiro, Micromedical instruments, England) and FENO (No Breath, Bedfont Medical instruments, England).
Sponsors
Vice chancellor for research, Islamic Azad University- Mashhad Branch
Eligibility
Sex/Gender
All
Age
12 Years to 91 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Resistant asthma to Inhaled corticosteroid, long acting beta 2 agonist, antileukotrien and theophyllin Exclusion criteria: 1- Respiratory infection 2- Fair Treatment with controller drugs 3- Not cooperative with project 4- congestive heart failure 5- Gastroesophageal reflux 6- Rhinosinusitis, 7- pregnancy 8- smoking 9- non asthmatic other lung disease and non pulmonary disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FEV1. Timepoint: before treatment and one month after treatment. Method of measurement: spirometry superspiro, Micromedical company, England.;Exhaled Nitric oxide (FENO). Timepoint: before treatment and one month after treatment. Method of measurement: Chemiluminescence instrument, No Breath, Bedfont company, England.;ACT Questionnaire. Timepoint: before treatment and one month after treatment. Method of measurement: Validated Asthma control test Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-17. Timepoint: Before treatment and One month after treatment. Method of measurement: ELIZA- Qiagen company Tehran Iran.;INF- Gamma. Timepoint: Before treatment and One month after treatment. Method of measurement: ELIZA- Qiagen company Tehran Iran. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Mirsadraee
Islamic Azad University- Mashhad Branch
Outcome results
None listed